同种异体复合组织移植的优势与风险  

ADVANTAGES AND DISADVANTAGES OF COMPOSITE TISSUE ALLOTRANSPLANTATION

作　　者：杨阳[1] 卢丙仑[1] 张辉[1] 夏炜[1] 易成刚[1] 郭树忠[1] 

机构地区：[1]第四军医大学西京医院全军整形外科研究所,西安710032

出　　处：《中国修复重建外科杂志》2009年第12期1497-1501,共5页Chinese Journal of Reparative and Reconstructive Surgery

基　　金：国家自然科学基金重点资助项目(30830102)~~

摘　　要：目的综述同种异体复合组织移植的研究进展,分析其优势及不足,展望可能的发展方向。方法广泛查阅同种异体复合组织移植相关文献,从常规修复重建外科治疗的局限性、同种异体复合组织移植的定义、潜在优势及治疗风险等方面进行综述。结果国内外同种异体复合组织移植的临床实践表明其疗效优于常规修复重建方法,但免疫抑制疗法带来的风险仍然是同种异体复合组织移植推广于临床的主要制约因素。结论免疫抑制治疗的发展为同种异体复合组织移植开拓了巨大发展前景,如何降低免疫抑制治疗风险将是今后同种异体复合组织移植领域的主要研究方向。Objective To review the research progress of composite tissue allotransplantation （CTA）,analyze the superiority and the inferiority,and inform the possible direction of further research. Methods Literature concerning CTA was reviewed and analyzed in terms of the limits of conventional reparative and reconstructive surgery,the definition of CTA,potential advantages,and treatment risks. Results The clinical research of CTA both at home and abroad proved that the therapeutic effect of CTA was better than that of conventional reparative and reconstructive surgery. However,the risks resulting from immunosuppressive therapy were still the primary factors restraining the wide clinical application of CTA. Conclusion The development of immunosuppressive therapy explores a great development potential for the CTA,and how to decrease the treatment risk of immunosuppressive therapy will be the main research direction in the field of CTA.

关 键 词：同种异体复合组织移植 免疫抑制 修复重建 

分 类 号：R622[医药卫生—整形外科] R64[医药卫生—外科学]